Skip to main content

4 Result(s)

within Jasgit C. Sachdev Remove this filter

and

  1. Article

    Open Access

    Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial

    New immuno-oncology therapies targeting programmed cell death receptor 1 (PD-1) have improved patient outcomes in a broad range of cancers. The objective of this analysis was to evaluate the PK, pharmacodynami...

    Amita Patnaik, Glen J. Weiss, Drew W. Rasco… in Cancer Chemotherapy and Pharmacology (2022)

    Download PDF (745 KB) View Article

  2. Article

    Open Access

    Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase

    Metastatic breast cancer (mBC) remains incurable and is associated with low survival rates. This study assessed the efficacy and safety of liposomal irinotecan in heavily pretreated patients with mBC, with or ...

    Jasgit C. Sachdev, Pamela Munster… in Breast Cancer Research and Treatment (2021)

    Download PDF (928 KB) View Article

  3. No Access

    Article

    Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy

    TTC-352 is a selective human estrogen receptor (ER) partial agonist developed for treatment of hormone-refractory ER + breast cancer.

    Arkadiusz Z. Dudek, Li C. Liu, James H. Fischer… in Breast Cancer Research and Treatment (2020)

  4. No Access

    Chapter

    Update on Precision Medicine in Breast Cancer

    Precision medicine approaches have found applications in the treatment of several tumor types and have led to rapid advancement in the number of available therapies for some difficult-to-treat diseases. In com...

    Jasgit C. Sachdev, Ana C. Sandoval… in Precision Medicine in Cancer Therapy (2019)